# Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

> **NCT01482143** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** AFQ056

## Key facts

- **NCT ID:** NCT01482143
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482143, "Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01482143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*